Xtant Medical Holdings, Inc. (XTNT)
NYSEAMERICAN: XTNT · Real-Time Price · USD
0.6300
+0.0187 (3.06%)
Aug 28, 2025, 4:00 PM - Market closed
Xtant Medical Holdings Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Xtant Medical Holdings.
Price Target: $ (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Xtant Medical Holdings.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $2 → $3 | Strong Buy | Maintains | $2 → $3 | +376.19% | May 16, 2024 |
| BTIG | BTIG | Strong Buy Initiates $2 | Strong Buy | Initiates | $2 | +217.46% | Dec 5, 2023 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $1 → $1.2 | Strong Buy | Maintains | $1 → $1.2 | +90.48% | Jul 11, 2023 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $1 | Strong Buy | Initiates | $1 | +58.73% | Apr 26, 2023 |
Financial Forecast
Revenue This Year
132.55M
from 117.27M
Increased by 13.03%
Revenue Next Year
120.67M
from 132.55M
Decreased by -8.96%
EPS This Year
-0.02
from -0.12
EPS Next Year
-0.02
from -0.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 140.5M | 138.8M | |
| Avg | 132.6M | 120.7M | |
| Low | 123.6M | 102.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 19.8% | 4.7% | |
| Avg | 13.0% | -9.0% | |
| Low | 5.4% | -22.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.01 | - | |
| Avg | -0.02 | -0.02 | |
| Low | -0.03 | -0.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.